Oxygen Concentrators Market size is estimated to be valued at USD 2.6 Bn in 2025 and is expected to reach USD 4.88 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of9.4% from 2025 to 2032.
Growth is driven by the rising prevalence of chronic respiratory diseases, increasing demand for portable and pulse-flow concentrators, and strong adoption in hospital and home-care settings. North America leads the market due to technological advances and strategic acquisitions, while Asia Pacific is the fastest-growing region. Key trends include smart, IoT-enabled devices and NGO-led innovations, though product recalls remain a notable challenge.
|
Event |
Description and Impact |
|
Aging Population Demographics and Respiratory Disease Surge (Macro-Level) |
|
|
Healthcare Digitalization and Technology Integration (Nano-Level) |
|
|
Global Supply Chain Semiconductor Shortages (Macro-Level) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The oxygen concentrators pipeline is expanding steadily, driven by advancements in portability, smart technology, and personalized therapy. In the near term (2025–2027), key players like Philips and Inogen are launching IoT-enabled portable models with remote monitoring, supporting the shift toward home-based care. AI-powered dosing systems are also entering advanced development stages, enabling real-time adjustment of oxygen flow based on patient vitals.
By 2028, membrane-based concentrators—noted for their lightweight and quiet performance—are expected to reach commercial readiness, alongside wearable designs like backpack units targeting mobile COPD users. Mid-stage projects are also exploring closed-loop oxygen delivery, integrating respiratory sensors to tailor therapy dynamically.
In preclinical development, companies are focusing on smart sensor-based platforms, combining SpO₂ tracking with machine learning to deliver adaptive care. Major trends include battery-efficient hardware, AI integration, and compact form factors for use beyond hospitals. Regulatory momentum—such as FDA clearances and CE fast-tracks—is accelerating innovation, positioning the market for a new generation of connected, intelligent oxygen systems.
The oxygen concentrators market value is supported by a dynamic and steadily expanding patent landscape, where over 70% of active patents are held by major industry leaders including Philips Respironics, Inogen, Invacare Corporation, CAIRE Inc., and Drive DeVilbiss Healthcare. Core areas of innovation include lightweight portable concentrator designs, pulse-dose and continuous-flow dual-mode systems, noise reduction mechanisms, and energy-efficient battery integration.
Recent patent filings emphasize advancements in IoT-enabled monitoring, AI-driven oxygen flow adjustment, and wearable concentrator configurations, highlighting the shift toward connected and personalized respiratory care therapy. Intellectual property around integrated sensor arrays and adaptive dosing algorithms is also gaining traction, reflecting industry focus on improving patient comfort and compliance.
Startups and research institutions are contributing with early-stage patents in membrane-based oxygen separation, solid-state concentrators, and multi-gas delivery systems, signalling future diversification in design platforms and clinical use cases.
The United States and China dominate global patent activity, followed by Japan and key European markets. This competitive patent environment supports ongoing innovation, strengthens market positions, and raises entry barriers for emerging players in the respiratory care sector.
The global reimbursement landscape for oxygen concentrators is diverse and influenced by public health coverage, homecare policies, and device classification. In the U.S., reimbursement is structured through HCPCS codes (e.g., E1390 for stationary and E1392 for portable units), with Medicare Part B covering 80% of the approved cost for medically necessary use, subject to deductible. CMS applies a monthly capped rental model, typically reimbursing up to 36 months, followed by maintenance payments for continued use.
Private insurers like Cigna and Aetna follow similar models but may require prior authorization and documentation of arterial blood gas results or pulse oximetry. Reimbursement levels vary, often exceeding Medicare rates but with stricter utilization reviews.
In Europe, policies differ by country. The UK's NHS covers oxygen therapy under long-term condition support, with equipment provided through regional contracts. In Germany, reimbursement is regulated under statutory health insurance (GKV), based on therapeutic necessity certified by pulmonologists.
In Asia-Pacific, Japan covers oxygen therapy under the national insurance system with reimbursement tied to disease severity and oxygen flow rate. Australia funds oxygen concentrators under the State and Territory Programs, often with eligibility based on blood oxygen thresholds.
Oxygen concentrators are a frontline therapy in managing chronic and acute respiratory conditions, with prescriber preferences shaped by disease severity, care setting, and patient mobility needs.
In chronic obstructive pulmonary disease (COPD), pulmonologists prefer portable oxygen concentrators (POCs) with pulse-dose delivery for ambulatory patients, enabling mobility and adherence to long-term oxygen therapy (LTOT). Oxygen concentrators for sports recovery typically involve stationary units with continuous flow, which help athletes enhance muscle repair and oxygenation during nighttime rest or after intense training sessions.
For interstitial lung disease (ILD) and pulmonary fibrosis, specialists prioritize high-flow units with reliable oxygen purity, often integrating backup battery systems to support uninterrupted therapy. Cardiologists managing congestive heart failure (CHF) in oxygen-dependent patients recommend concentrators with real-time oxygen saturation monitoring for personalized flow adjustment.
In pediatric care, clinicians opt for low-decibel, compact units that reduce noise sensitivity and support home-based therapy, especially in neonatal bronchopulmonary dysplasia cases. Emergency physicians prefer easily deployable, rapid-start concentrators in field triage and ambulance settings, especially where cylinder oxygen is unavailable.
Rising adoption of organic strategies, including key regulatory milestones, is expected to drive the latest oxygen concentrators market trends and fuel global growth throughout the forecast period. For instance, on January 10, 2023, Inogen, Inc., one of the medical technology companies offering innovative respiratory products for use in the homecare setting, announced that it had passed regulatory milestones in the U.S. and Europe to support its line of portable oxygen concentrator solutions.
Inogen acquired approval under the European Medical Device Regulation (EU MDR) from its notified authority, the British Standards Institution (BSI), in December 2022, allowing it to sell and market the Inogen One G4 and the improved Inogen One G5 portable oxygen concentrators in the EU.
The increasing prevalence of chronic respiratory diseases is expected to increase the demand for oxygen concentrators, thereby driving the global oxygen concentrators market’s growth.
For instance, on April 25, 2023, the Institute of Health Metrics and Evaluation published data according to which the prevalence of chronic respiratory diseases in 2019 was 454.6 Billion cases globally. While the prevalence of chronic respiratory diseases has increased by 39.8% from 1990 to 2019. Hence, this is expected to fuel the oxygen concentrators markets growth over the forecast period.
The market is segmented into portable and stationary. Within this, the portable segment is anticipated to drive significant oxygen concentrators market growth and maintain a dominant position globally throughout the forecast period, and this is attributed to the increasing launch of portable oxygen concentrators.
The market is segmented into pulse flow and continuous flow. Out of which, pulse flow is expected to dominate the market over the forecast period, and this is attributed to the introduction of pulse flow portable oxygen concentrators in the market.
The market is segmented into hospitals, home care, and ambulatory surgical centers. Out of which, hospital is expected to dominate the market over the forecast period, and this is attributed to the increasing number of installations of oxygen concentrators in hospitals.
To learn more about this report, Download Free Sample
The oxygen concentrators market demand is expected to be highest in North America, which will hold a dominant position globally over the forecast period. North America is estimated to hold 33.50% of the market share in 2025.
The global oxygen concentrators market is expected to witness significant growth in the coming years, driven by increasing inorganic strategies such as acquisition by key players, which is contributing to the growth of the oxygen concentrators market in the North America region.
For instance, in May 2021, OxyGo LLC, one of the leaders in lightweight portable oxygen concentrators based in the U.S., announced that it had acquired LIFE Corporation, a manufacturer of medical devices that specializes in portable emergency oxygen and CPR administration equipment. This acquisition will help OxyGo LLC expand its oxygen expertise even further by providing the best products and services, thereby driving demand for oxygen concentrators in the U.S.
Asia Pacific is the fastest-growing region, supported by improved healthcare infrastructure in countries like China and India, and strategic partnerships expanding local supply chains.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 2.6 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 9.4% | 2032 Value Projection: | USD 4.88 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Inogen Inc., Invacare Corporation, OxygenToGo, LLC, Koninklijke Philips N.V., ResMed Inc., Drive DeVilbiss Healthcare LLC, Precision Medical, Inc., Besco Medical Co. Ltd., O2 Concepts, LLC, and GCE Group |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Non-profit organizations are involved in various increasing inorganic strategies, such as partnerships to provide the portable oxygen concentrators, which is also expected to boost demand oxygen concentrators in Asia Pacific region. For instance, In June 2021, O2 Concepts, one of the leading manufacturers of oxygen concentrators, launched the Oxlife Independence portable oxygen concentrator. Known for its durability and reliability, it was designed to meet the needs of active users who require oxygen therapy while on the move.
*Definition: An oxygen concentrator is a medical device designed to extract and concentrate oxygen from the surrounding air. It provides a continuous and reliable source of oxygen for individuals who have low oxygen levels in their blood, typically due to respiratory conditions like chronic obstructive pulmonary disease (COPD), asthma, or other chronic lung disorders.
Share
Share
About Author
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
